Lawmakers who count pharmaceutical companies among their biggest contributors lead the opposition to a health care proposal that would cut costs by allowing generic drugs to compete sooner with pricey biotechnology drugs, campaign-finance records show.They're not interested in what's best for you, but rather what's best for them.
Sen. Orrin Hatch, R-Utah, has helped lead Senate efforts to give drug companies 12 years of exclusive rights to sell biotech drugs, rather than seven as proposed by President Obama. Hatch has received nearly $1.3 million from the employees and political action committees of drug and health products companies since 1989, making the industry his largest contributor, according to data compiled by the non-partisan Center for Responsive Politics.
Wednesday, July 29, 2009
I have a feeling something very similar to this kind of bankrolling is the reason why many in Congress are opposing health care reform (i.e. could it be corporate/lobbyist $$$?):
Posted by Grey Matter at 6:23 AM